During plenary 2 of our North American Cystic Fibrosis Conference, Lucas Hoffman, MD, PhD, and Natalie West, MD, MHS, discuss the current landscape of CF infections, including the latest clinical research.
Dr. Hoffman will provide an overview of infections in cystic fibrosis, how they are changing in the context of highly effective modulators, and what challenges are emerging. Dr. West will focus on the development of new therapeutics in CF and describe novel approaches to managing CF infections with the goal of improving the lives of all people with CF.
0:00:00 | NACFC 2023: “Micro-Management”: The Changing Face of Infections in CF
01:31 | Steven Rowe, MD, executive vice president and chief scientific officer of the CF Foundation, awards the Dorothy Andersen and Paul di Sant’Agnese Distinguished Scientific Achievement Award to Robert J. Bridges, PhD, professor emeritus and director of cystic fibrosis research at Rosalind Franklin University of Medicine and Science.
08:24 | Introduction to the plenary and recap of the Infection Research Initiative
14:50 | What are the bacteria that infect people with CF?
17:24 | How has the prevalence of CF respiratory pathogens changed over the years?
18:52 | How do we detect CF respiratory infections?
20:01 | What are the problems with diagnosing infections?
21:14 | What are some of the techniques being developed to address the problems with diagnosing infections?
22:41 | What have we learned about CF infections?
25:57 | What are the upsides and downsides of using antibiotics in CF?
28:38 | What are the unintended effects of antibiotics on the bacteria living in people with CF?
30:22 | People with CF are producing less sputum — another problem in diagnosing and treating infections
32:38 | What are some of the up-and-coming techniques for the detection and diagnosis of infections?
35:56 | What do ongoing research studies tell us about the effects of CFTR modulators on respiratory microbiology?
38:29 | What can we learn from microbiology in other countries? What are the lessons from Europe?
41:02 | Nick Kelly, an adult with CF, explains why it is important to find new and better treatments for infections
45:16 | How will we treat CF infections in those on and off Trikafta®?
47:59 | What have we learned and where are we going — pulmonary exacerbation trials
57:50 | How many antibiotics should we use to treat infections? The STOP360 trial.
1:00:33 | What did the STOP-2 pulmonary exacerbation trial tell us?
1:05:15 | What is the STOP-PEDS trial?
1:07:09 | Why do women with CF have worse outcomes than men?
1:08:58 | Will infections have the same implications in the era of Trikafta?
1:10:19 | What anti-infectives are in development with the support of the CF Foundation?
1:10:37 | What is bacteriophage therapy?
1:12:13 | What were the results of the Armata bacteriophage trial?
1:13:35 | What were the results of the BiomX bacteriophage trial?
Originally recorded November 3, 2023.
